NCT04042493 is a NA clinical trial of Connect for Health in Overweight and Obesity, sponsored by Massachusetts General Hospital.

Who is sponsoring NCT04042493?

NCT04042493 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT04042493?

Interventions in NCT04042493: Connect for Health.

What condition does NCT04042493 study?

NCT04042493 studies Overweight and Obesity, Severe Obesity.

Is NCT04042493 still recruiting?

NCT04042493 is currently completed. Last updated 22 March 2023.

Last reviewed 2023-03-22 · How we verify

NCT04042493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Connect for Health Pediatric Weight Management Program

Completed NA Last updated 22 March 2023

What this trial tests

NA trial testing Connect for Health in Overweight and Obesity in 19,304 participants. Completed in 31 July 2022.

Timeline

19 November 2019

Primary endpoint
30 April 2022

31 July 2022

Quick facts

Lead sponsor	Massachusetts General Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	19,304
Start date	19 November 2019
Primary completion	30 April 2022
Estimated completion	31 July 2022
Sites	3 locations across United States

Drugs / interventions tested

Connect for Health

Conditions studied

Overweight and Obesity — all drugs for Overweight and Obesity →
Severe Obesity — all drugs for Severe Obesity →

Sponsor

Massachusetts General Hospital

Who can join

Adults 2 to 12, any sex, with Overweight and Obesity or Severe Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall aim of this study is to disseminate the evidence-based Connect for Health program, specifically targeting pediatric primary care practices that deliver care to low-income children in the US who have a disproportionately high prevalence of childhood obesity and evaluate the effectiveness of the program implementation and dissemination.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Engaging stakeholders in the adaptation of the <i>Connect for Health</i> pediatric weight management program for national implementation.
Simione M, Frost HM, Cournoyer R, Mini FN, et al · · 2020 · cited 15× · PMID 32885211 · DOI 10.1186/s43058-020-00047-z
Implementation of the <i>Connect for Health</i> pediatric weight management program: study protocol and baseline characteristics.
Simione M, Farrar-Muir H, Mini FN, Perkins ME, et al · · 2021 · cited 8× · PMID 34024120 · DOI 10.2217/cer-2021-0076
Adapting Connect for Health pediatric weight management program for telehealth in response to the COVID-19 pandemic.
Simione M, Aschbrenner K, Farrar-Muir H, Luo M, et al · · 2023 · cited 4× · PMID 37974245 · DOI 10.1186/s43058-023-00523-2
Adapting Connect for Health Pediatric Weight Management Program for Telehealth in Response to the COVID-19 Pandemic
Simione M, Aschbrenner K, Farrar-Muir H, Luo M, et al · · 2023 · DOI 10.21203/rs.3.rs-2426344/v1
Implementation of the Connect for Health Pediatric Weight Management Program: Study Protocol and Baseline Characteristics
Simione M, Farrar-Muir H, Mini FN, Perkins ME, et al · · 2020 · DOI 10.21203/rs.3.rs-115362/v1
Engaging Stakeholders in the Adaptation of the Connect for Health Pediatric Weight Management Program for National Implementation
Simione M, Frost HM, Cournoyer R, Mini FN, et al · · 2020 · DOI 10.21203/rs.2.23273/v2

Verify or expand the search:

Other recruiting trials for Overweight and Obesity

Currently open trials in the same condition.

NCT06282952 — Health Outcomes in C-Section Infants With Fecal Microbiota Transplantation · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07230496 — A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healt · Phase 1 · recruiting
NCT07313761 — A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered · Phase 1 · active not recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting

Other Massachusetts General Hospital trials

Trials by the same sponsor.

NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04042493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
Last refreshed: 22 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04042493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing